Eye drug developer TearClear has appointed Robert Dempsey to serve as its CEO. Demsey was most recently global head of ophthalmology at Shire, which was acquired by Takeda Pharmaceutical (NYSE: [[ticker:TAK]]). TearClear says Dempsey’s hire comes as the company approaches the initial close of a Series B round of funding that could reach up to $25 million. The Boston-based company says its technology captures preservatives in drugs before they reach the surface of the eye.
Author: Frank Vinluan
Xconomy Editor Frank Vinluan is a business journalist with experience covering technology and life sciences. Based in Raleigh, he was a staff writer at the Triangle Business Journal covering technology, biotechnology and energy before joining MedCityNews.com as North Carolina bureau chief. Prior to moving to North Carolina’s Research Triangle in 2007 he held business reporting positions at The Des Moines Register and The Seattle Times.
View all posts by Frank Vinluan
